R D Moore

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Human immunodeficiency virus infection, anemia, and survival
    R D Moore
    Johns Hopkins Hospital, Baltimore, Maryland 21205, USA
    Clin Infect Dis 29:44-9. 1999
  2. ncbi request reprint Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients
    R D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Am J Hematol 60:116-20. 1999
  3. ncbi request reprint Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group
    R E Chaisson
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205
    Am Rev Respir Dis 146:285-9. 1992
  4. ncbi request reprint Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group
    J E Gallant
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    Arch Intern Med 154:566-72. 1994
  5. pmc Emergency department utilization among HIV-infected patients in a multisite multistate study
    J S Josephs
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    HIV Med 11:74-84. 2010
  6. ncbi request reprint Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group
    R D Moore
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland
    AIDS 6:671-7. 1992
  7. ncbi request reprint Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine
    R D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    JAMA 265:2208-11. 1991
  8. ncbi request reprint Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection
    G M Lucas
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Acquir Immune Defic Syndr 27:251-9. 2001
  9. pmc Hospitalization risk following initiation of highly active antiretroviral therapy
    S A Berry
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287 2100, USA
    HIV Med 11:289-98. 2010
  10. ncbi request reprint Self-reported antiretroviral therapy in injection drug users
    D D Celentano
    Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    JAMA 280:544-6. 1998

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Human immunodeficiency virus infection, anemia, and survival
    R D Moore
    Johns Hopkins Hospital, Baltimore, Maryland 21205, USA
    Clin Infect Dis 29:44-9. 1999
    ..If these results are confirmed, the link between r-HuEPO and decreased risk of death in HIV-infected patients with anemia will be further strengthened...
  2. ncbi request reprint Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients
    R D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Am J Hematol 60:116-20. 1999
    ..Schistocytosis and a TMA-like syndrome are relatively common in hospitalized HIV-infected patients. This syndrome may contribute to mortality and morbidity, particularly in patients with more advanced disease...
  3. ncbi request reprint Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group
    R E Chaisson
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205
    Am Rev Respir Dis 146:285-9. 1992
    ..100 x 10(9)/L, baseline AIDS diagnosis, and transfusion independently predicted an increased risk of death.(ABSTRACT TRUNCATED AT 250 WORDS)..
  4. ncbi request reprint Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group
    J E Gallant
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    Arch Intern Med 154:566-72. 1994
    ..This large cohort study provides further evidence for an association between risk for cytomegalovirus infection and KS...
  5. pmc Emergency department utilization among HIV-infected patients in a multisite multistate study
    J S Josephs
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    HIV Med 11:74-84. 2010
    ..The aim of this study was to examine Emergency Department (ED) utilization and clinical and sociodemographic correlates of ED use among HIV-infected patients...
  6. ncbi request reprint Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group
    R D Moore
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland
    AIDS 6:671-7. 1992
    ..These CD4+ lymphocyte count-stratified estimates of disease progression should provide prognostic information useful in the clinical management of advanced disease and the design of future studies...
  7. ncbi request reprint Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine
    R D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    JAMA 265:2208-11. 1991
    ..Our study demonstrates a relatively high incidence of NHL in patients with advanced human immunodeficiency virus disease who are undergoing antiretroviral therapy and suggests possible risk factors for development of NHL...
  8. ncbi request reprint Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection
    G M Lucas
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Acquir Immune Defic Syndr 27:251-9. 2001
    ..To identify the effects of substance abuse status (active, former, and never) on utilization of highly active antiretroviral therapy (HAART), medication adherence, and virologic and immunologic responses to therapy...
  9. pmc Hospitalization risk following initiation of highly active antiretroviral therapy
    S A Berry
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287 2100, USA
    HIV Med 11:289-98. 2010
    ..The primary objective of this study was to determine hospitalization rates over time in the year after HAART initiation for virological responders and nonresponders...
  10. ncbi request reprint Self-reported antiretroviral therapy in injection drug users
    D D Celentano
    Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
    JAMA 280:544-6. 1998
    ....
  11. ncbi request reprint Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
    M S Sulkowski
    Department of Medicine, Johns Hopkins University Schools of Medicine, Baltimore, MD 21287, USA
    JAMA 283:74-80. 2000
    ..Use of antiretroviral drugs, including protease inhibitors, for treatment of human immunodeficiency virus (HIV) infection has been anecdotally associated with hepatotoxicity, particularly in persons coinfected with hepatitis C or B virus...
  12. ncbi request reprint Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. Zidovudine Epidemiology Study Group
    M J Glesby
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205
    J Infect Dis 168:1264-8. 1993
    ..Thus, herpes zoster is relatively common in advanced HIV infection and its initial occurrence late in disease may indicate improved prognosis...
  13. ncbi request reprint Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group
    J E Gallant
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 6220, USA
    J Infect Dis 172:346-52. 1995
    ..In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival...
  14. ncbi request reprint Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease
    E J Erbelding
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Antivir Ther 2:71-7. 1997
    ..001); and combination use of acyclovir and zidovudine associated with a RH of 1.062 (P = 0.788). Therefore we conclude that the use of acyclovir is not associated with prolonged survival in this cohort of HIV-infected patients...
  15. ncbi request reprint Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world
    T R Sterling
    Department of Medicine, Keesler Medical Center, Keesler AFB, Mississippi, USA
    Int J Tuberc Lung Dis 3:248-54. 1999
    ..The developing world...
  16. pmc The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era
    M D Burkey
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    HIV Med 9:858-62. 2008
    ..To define the incidence and risk factors for methicillin resistant Staphylococcus aureus (MRSA) bacteraemia in an HIV-infected population...
  17. ncbi request reprint Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    AIDS 15:617-20. 2001
    ..We investigated the incidence of pancreatitis in patients using nucleoside analogues with or without hydroxyurea...
  18. ncbi request reprint Predictors of outpatient treatment retention: patient versus substance use characteristics
    M E McCaul
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Comprehensive Women s Center, 911 N Broadway, Baltimore, MD 21205, USA
    Drug Alcohol Depend 62:9-17. 2001
    ....
  19. ncbi request reprint An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age
    Y C Chang
    Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
    Blood 85:1111-7. 1995
    ..The variation within each FCP phenotype is modulated by factors associated with the three common beta-globin haplotypes and other as yet unidentified factor(s)...
  20. ncbi request reprint Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy
    K E Poundstone
    Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, USA
    AIDS 15:1115-23. 2001
    ..No significant differences were detected by race or other HIV transmission risk group. CONCLUSION: Disease-free survival time was extended with the use of HAART, but these gains were not equally distributed by sex and IDU in our cohort...
  21. ncbi request reprint A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users
    R E Chaisson
    Center for Tuberculosis Research, Johns Hopkins University, and the Baltimore City Health Department, Baltimore, Maryland 21231-1001, USA
    Am J Med 110:610-5. 2001
    ..More widespread use of supervised care could contribute to reductions in tuberculosis rates among drug users and possibly other high-risk groups...
  22. ncbi request reprint Cost effectiveness of combination HIV therapy: 3 years later
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Pharmacoeconomics 17:325-30. 2000
    ..Economic analyses of HIV infection must evolve in tandem with therapeutic changes to continue to be relevant to policy makers, payors of care, and those who provide and receive HIV care...
  23. ncbi request reprint Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia
    R D Moore
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Am J Hematol 64:26-31. 2000
    ..If hydroxyurea can prevent development of chronic organ damage, long-term savings may be even greater...
  24. ncbi request reprint Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy
    K A Gebo
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument St, Baltimore, MD 21205
    J Acquir Immune Defic Syndr 27:143-52. 2001
    ....
  25. pmc Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort
    A A Chaudhry
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    HIV Med 10:133-42. 2009
    ....